Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016): Complete Statistical AnalysisIndependent statistical analysis of Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016): primary endpoint results, effect estimate with confidence interval,…
- Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03055013).
- Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b): Complete Statistical AnalysisIndependent statistical analysis of NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b): primary endpoint results, effect estimate with…
- NO-ASPIRATEIndependent statistical analysis of Oral Suction Intervention to Reduce Aspiration and Ventilator Events: NO-ASPIRATE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02284178).
- NO-COVID-19Independent statistical analysis of Inhaled Nitric Oxide for Preventing Progression in COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04388683).
- no-cryIndependent statistical analysis of Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- No-POPPYIndependent statistical analysis of Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- NO-UTIIndependent statistical analysis of Short-course Methenamine Hippurate for Prevention of Post-operative UTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02358993).
- NOAHIndependent statistical analysis of Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease: Complete Statistical AnalysisIndependent statistical analysis of Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02114216).
- NOCTIndependent statistical analysis of Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults: primary endpoint…
- NODE-1Independent statistical analysis of Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- NOH303Independent statistical analysis of Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NOH304Independent statistical analysis of Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NOLANIndependent statistical analysis of NOLAN: Naproxen or Loratadine and Neulasta: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01712009).
- NOMIIndependent statistical analysis of Nitric Oxide in Myocardial Infarction Size: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00568061).
- Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma: primary endpoint…
- Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ: Complete Statistical AnalysisIndependent statistical analysis of Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment: Complete Statistical AnalysisIndependent statistical analysis of Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04435769).
- Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation: Complete Statistical AnalysisIndependent statistical analysis of Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size…
- Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin: Complete Statistical AnalysisIndependent statistical analysis of Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Non-Invasive Characterization in Cardiac Sarcoidosis: Complete Statistical AnalysisIndependent statistical analysis of Non-Invasive Characterization in Cardiac Sarcoidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02017522).
- Non-Invasive Cooling of Fat Cells: Complete Statistical AnalysisIndependent statistical analysis of Non-Invasive Cooling of Fat Cells: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00762437).
- Non-invasive Estimation of CSF Pressure Using MRI in Patients With Spontaneous Intracranial Hypotension: Complete Statistical AnalysisIndependent statistical analysis of Non-invasive Estimation of CSF Pressure Using MRI in Patients With Spontaneous Intracranial Hypotension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Non-invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders: Complete Statistical AnalysisIndependent statistical analysis of Non-invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Non-invasive Nerve Stimulation and Cognitive Training to Improve Cognitive Performance in Healthy Older Adults: Complete Statistical AnalysisIndependent statistical analysis of Non-invasive Nerve Stimulation and Cognitive Training to Improve Cognitive Performance in Healthy Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Non-Invasive Neurostimulation for the Prevention of Chronic Migraine: Complete Statistical AnalysisIndependent statistical analysis of Non-Invasive Neurostimulation for the Prevention of Chronic Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01667250).
- Non-invasive Tidal Volume Monitoring Using the Linshom Respiratory Monitoring Device: Complete Statistical AnalysisIndependent statistical analysis of Non-invasive Tidal Volume Monitoring Using the Linshom Respiratory Monitoring Device: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03279458).
- Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Complete Statistical AnalysisIndependent statistical analysis of Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Non-motor Symptoms (Depressive Symptoms) of Parkinson’s Disease and Their Course Under Pramipexole Treatment: Complete Statistical AnalysisIndependent statistical analysis of Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Non-Myeloablative Allogeneic Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Non-Myeloablative Allogeneic Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00525876).
- Non-Pharmacological Interventions on Sleep in Post-Acute Rehabilitation: Complete Statistical AnalysisIndependent statistical analysis of Non-Pharmacological Interventions on Sleep in Post-Acute Rehabilitation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00333619).
- Non-Pharmacological Treatments for Insomnia in Chronic Traumatic Brain Injury: Complete Statistical AnalysisIndependent statistical analysis of Non-Pharmacological Treatments for Insomnia in Chronic Traumatic Brain Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03261674).
- Non-Surgical Treatment for Rotator-Cuff Tears Using Platelet-Rich-Plasma: Complete Statistical AnalysisIndependent statistical analysis of Non-Surgical Treatment for Rotator-Cuff Tears Using Platelet-Rich-Plasma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02246530).
- Nonopioid Analgesia After Rotator Cuff Repair: Complete Statistical AnalysisIndependent statistical analysis of Nonopioid Analgesia After Rotator Cuff Repair: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03818919).
- NOPHOCPG2Independent statistical analysis of Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- nOPV2M4aIndependent statistical analysis of Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Norovirus Bivalent-Vaccine Efficacy Study: Complete Statistical AnalysisIndependent statistical analysis of Norovirus Bivalent-Vaccine Efficacy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01609257).